Amalgamated Bank Has $550,000 Stake in Loxo Oncology Inc (LOXO)

Amalgamated Bank increased its stake in Loxo Oncology Inc (NASDAQ:LOXO) by 149.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,928 shares of the biopharmaceutical company’s stock after acquiring an additional 2,353 shares during the quarter. Amalgamated Bank’s holdings in Loxo Oncology were worth $550,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Dorsey Wright & Associates increased its stake in shares of Loxo Oncology by 20.0% in the 4th quarter. Dorsey Wright & Associates now owns 312 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 52 shares in the last quarter. Strs Ohio increased its stake in Loxo Oncology by 0.9% during the 4th quarter. Strs Ohio now owns 10,900 shares of the biopharmaceutical company’s stock valued at $1,526,000 after purchasing an additional 100 shares in the last quarter. Cornerstone Advisors Inc. increased its stake in Loxo Oncology by 46.0% during the 4th quarter. Cornerstone Advisors Inc. now owns 387 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 122 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Loxo Oncology by 10.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,477 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 143 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its stake in Loxo Oncology by 177.0% during the 4th quarter. Meeder Asset Management Inc. now owns 338 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 216 shares in the last quarter. Institutional investors own 96.49% of the company’s stock.

LOXO traded up $234.66 during mid-day trading on Wednesday, reaching $234.66. 400 shares of the stock were exchanged, compared to its average volume of 565,561. The company has a market capitalization of $7.18 billion, a price-to-earnings ratio of -44.19 and a beta of 2.51. Loxo Oncology Inc has a 1 year low of $101.70 and a 1 year high of $234.93.

A number of analysts have commented on the stock. BidaskClub lowered shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Wednesday, February 13th. Citigroup lowered shares of Loxo Oncology from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 8th. Ifs Securities lowered shares of Loxo Oncology from an “outperform” rating to a “market perform” rating in a research note on Monday, January 7th. William Blair lowered shares of Loxo Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 17th. Finally, Leerink Swann lowered shares of Loxo Oncology from an “outperform” rating to a “market perform” rating in a research note on Monday, January 7th. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $198.58.

WARNING: This piece was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/25/loxo-oncology-inc-loxo-position-increased-by-amalgamated-bank.html.

About Loxo Oncology

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Read More: Dollar Cost Averaging

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.